A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles

Journal of Virology

Volumn 86, Issue 4, 2012, Pages 2347-2359

  Brandano, Laura ^a   Stevenson, Mario ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARTIC ACID; ENV PRECURSOR PROTEIN; GAG PROTEIN; GLUTAMIC ACID; GLYCINE; LYSINE; MATRIX PROTEIN; PROTEIN PRECURSOR; THREONINE; UNCLASSIFIED DRUG; VALINE; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL MEMBRANE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; MEMBRANE FUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CELL LINE; CONSERVED SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SEQUENCE ALIGNMENT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857088943     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06047-11     Document Type: Article

References (73)

1. Adachi A, et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Alfadhli A, Still A, Barklis E. 2009. Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids. J. Virol. 83:12196-12203.
3. Bhatia A, Campbell N, Panganiban A, Ratner L. 2007. Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix. Virology 369:47-54.
4. Bhattacharya J, Repik A, Clapham PR. 2006. Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes. J. Virol. 80:5292-5300.
5. Bukrinsky MI, et al. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365:666-669.
6. Camaur D, Gallay P, Swingler S, Trono D. 1997. Human immunodeficiency virus matrix tyrosine phosphorylation: characterization of the kinase and its substrate requirements. J. Virol. 71:6834-6841.
7. Cannon PM, et al. 1997. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J. Virol. 71:3474-3483.
8. Casella CR, Raffini LJ, Panganiban AT. 1997. Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. J. Virol. 228:294-306.
9. Cavrois M, De Noronha C, Greene WC. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:1151-1154.
10. Cosson P. 1996. Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J. 15:5783-5788.
11. Davis M, Jiang J, Zhou J, Freed EO, Aiken C. 2006. A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of envelope protein subunits gp120 and gp41. J. Virol. 80:2405-2417.
12. DeLano WL. 2002. The PYMOL user's manual. http:/www.pymol.org. Delano Scientific, San Carlos, CA.
13. Dorfman T, Mammano F, Haseltine WA, Göttlinger HG. 1994. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 68:1689-1696.
14. Dupont S, et al. 1999. A novel nuclear export activity in HIV-1 matrix protein required for viral replication. Nature 402:681-685.
15. Fäcke M, Janetzko A, Shoeman RL, Kräusslich HG. 1993. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J. Virol. 67:4972-4980.
16. Fassati A, Goff SP. 2001. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 75:3626-3635.
17. Freed EO. 1998. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251:1-15.
18. Freed EO, Englund G, Martin MA. 1995. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J. Virol. 69:3949-3954.
19. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA. 1994. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J. Virol. 68:5311-5320.
20. Freed EO, Martin MA. 1995. Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J. Virol. 69:1984-1989.
21. Freed EO, Martin MA. 1996. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J. Virol. 70:341-351.
22. Gallay P, Swingler S, Song J, Bushman F, Trono D. 1995. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell 83:569-576.
23. Göttlinger HG, Sodroski JG, Haseltine WA. 1989. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 86:5781-5785.
24. Haffar OK, Popov S, Dubrovsky L, Agostini I, Tang H. 2000. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J. Mol. Biol. 299:359-368.
25. Hannah R, Stroke I, Betz N. 2003. Beta-Glo® assay system: a luminescent β-galactosidase assay for multiple cell types and media. Cell Notes 6:16-18.
26. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI. 1996. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl. Acad. Sci. U. S. A. 93:3099-3104.
27. Kaplan AH, Swanstrom R. 1991. HIV-1 gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. U. S. A. 88:4528-4532.
28. Kaushik R, Ratner L. 2004. Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J. Virol. 78:2319-2326.
29. Kiernan RE, Ono A, Englund G, Freed EO. 1998. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J. Virol. 72:4116-4126.
30. Kunkel TA, Roberts JD, Zakour RA. 1987. Rapid and efficient sitespecific mutagenesis without phenotypic selection. Methods Enzymol. 155:16.
31. + T lymphocytes. J. Virol. 71:1443-1452.
32. Lodge R, Göttlinger HG, Gabuzda D, Cohen EA, Lemay G. 1994. The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells. J. Virol. 68:4857-4861.
33. Lopez-Verges S, Camus G, Blot G, Beauvoir R, Benearous R. 2006. Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions. Proc. Natl. Acad. Sci. U. S. A. 103:14947-14952.
34. Mammano F, et al. 1997. Truncation of the human immunodeficiency virus type 1 envelope glycoprotein allows efficient pseudotyping of Moloney murine leukemia virus particles and gene transfer into CD4+ cells. J. Virol. 71:3341-3345.
35. Mammano F, Kondo E, Sodroski J, Bukovsky A, Göttlinger HG. 1995. Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J. Virol. 69:3824-3830.
36. Massiah MA, et al. 1996. Comparison of theNMRand X-ray structures of the HIV-1 matrix protein: evidence for conformational changes during viral assembly. Protein Sci. 5:2391-2398.
37. Miller MD, Farnet CM, Bushman FD. 1997. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J. Virol. 71:5382-5390.
38. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. 2009. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:433-444.
39. Morikawa Y, et al. 1996. Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding. J. Biol. Chem. 271:2868-2873.
40. Morikawa Y, Zhang W, Hockley D, Nermut M, Jones I. 1998. Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix domain, p17. J. Virol. 72:7659-7663.
41. Murakami T, Ablan S, Freed EO, Tanaka Y. 2004. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J. Virol. 78:1026-1031.
42. Murakami T, Freed EO. 2000. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and helix 2 of the gp41 cytoplasmic tail. J. Virol. 74:3548-3554.
43. Murakami T, Freed EO. 2000. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc. Natl. Acad. Sci. U. S. A. 97:343-348.
44. Nermut M, et al. 1994. Fullerene-like organization of HIV Gag protein shell in virus-like particles produced by recombinant baculovirus. Virology 198:288-296.
45. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. 2004. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 101:14889-14894.
46. Ono A, Freed EO. 1999. Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J. Virol. 73:4136-4144.
47. Ono A, Huang M, Freed EO. 1997. Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions. J. Virol. 71:4409-4418.
48. Ono A, Orenstein JM, Freed EO. 2000. Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J. Virol. 74:2855-2866.
49. Paillart J, Göttlinger HG. 1999. Opposing effects of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J. Virol. 73:2604-2612.
50. Papsidero LD, Sheu M, Ruscetti FW. 1989. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J. Virol. 63:267-272.
51. Peden K, Emerman M, Montagnier L. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185:661-672.
52. Poiesz BJ, et al. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 77:7415-7419.
53. Rao Z, et al. 1995. Crystal structure of SIV matrix antigen and implications for virus assembly. Nature 378:743-747.
54. Reicin AS, Kaplana G, Paik S, Marmon S, Goff S. 1995. Sequences in the human immunodeficiency virus type 1 U3 region required for in vivo and in vitro integration. J. Virol. 69:5904-5907.
55. Reicin A, Ohagen A, Yin L, Hoglund S, Goff S. 1996. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J. Virol. 70:8645-8652.
56. Reil H, Bukovsky AA, Gelderblom HR, Göttlinger HG. 1998. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J. 17:2699-2708.
57. Saad JS, et al. 2006. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. U. S. A. 103:11364-11369.
58. Saad JS, et al. 2007. Point mutations in the HIV-1 matrix protein turn off the myristyl switch. J. Mol. Biol. 366:574-585.
59. Scarlata S, Ehrlich L, Carter C. 1998. Membrane-induced alterations in HIV-1 Gag and matrix protein-protein interactions. J. Mol. Biol. 277:161-167.
60. Swingler S, et al. 1997. The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J. Virol. 71:4372-4377.
61. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82:12585-12588.
62. Tang C, Ndassa Y, Summers MF. 2002. Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat. Struct. Biol. 9:537-543.
63. Tang C, et al. 2004. Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc. Natl. Acad. Sci. U. S. A. 101:517-522.
64. Von Schwedler U, Kornbluth RS, Trono D. 1994. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 91:6992-6996.
65. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
66. Welker R, Hohenberg H, Tessmer U, Huckhagel C, Krausslich HG. 2000. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74:1168-1177.
67. West JT, et al. 2002. Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation. J. Virol. 76:3338-3349.
68. Wyma DJ, Kotov A, Aiken C. 2000. Evidence for a stable interaction of gp41 with Pr55Gag in immature human immunodeficiency virus type 1 particles. J. Virol. 74:9381-9387.
69. Wyma DJ, et al. 2004. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J. Virol. 78:3429-3435.
70. Yu X, Yu QC, Lee TH, Essex M. 1992. The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J. Virol. 66:5667-5670.
71. Yu X, Yuan X, Matsuda Z, Lee TH, Essex M. 1992. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J. Virol. 66:4966-4971.
72. Yu Z, et al. 2005. The cellular HIV-1 Rev cofactor hRIP is required for viral replication. Proc. Natl. Acad. Sci. U. S. A. 102:4027-4032.
73. Zhou W, Resh M. 1996. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J. Virol. 70:8540-8548.